Related references
Note: Only part of the references are listed.Quantitative Prediction of CYP3A4-and CYP3A5-Mediated Drug Interactions
Yingying Guo et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Physiologically based pharmacokinetic modelling of oxycodone drug-drug interactions
Jaana Rytkonen et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2020)
Effects of repeated oral doses of ketoconazole on a sequential ascending single oral dose of fedratinib in healthy subjects
Ken Ogasawara et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2020)
Evaluation of Generic Methods to Predict Human Pharmacokinetics Using Physiologically Based PharmacokineticModel for Early Drug Discovery of Tyrosine Kinase Inhibitors
Hong-Can Ren et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2019)
Predictive Performance of Physiologically-Based Pharmacokinetic Models in Predicting Drug-Drug Interactions Involving Enzyme Modulation
Chia-Hsiang Hsueh et al.
CLINICAL PHARMACOKINETICS (2018)
Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban
Ruijuan Xu et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model
Kevin J. Freise et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Physiologically Based Pharmacokinetic Model Predictions of Panobinostat (LBH589) as a Victim and Perpetrator of Drug-Drug Interactions
Heidi J. Einolf et al.
DRUG METABOLISM AND DISPOSITION (2017)
A Physiologically-Based Pharmacokinetic Modeling Approach To Predict Drug-Drug Interactions of Sonidegib (LDE225) with Perpetrators of CYP3A in Cancer Patients
Heidi J. Einolf et al.
DRUG METABOLISM AND DISPOSITION (2017)
Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions
Chiho Ono et al.
DRUG METABOLISM AND DISPOSITION (2017)
Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug-Drug Interactions
Ruben de Kanter et al.
CLINICAL PHARMACOKINETICS (2016)
Best Practices for the Use of Itraconazole as a Replacement for Ketoconazole in Drug-Drug Interaction Studies
Lichuan Liu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Simulation and Prediction of the Drug-Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling
D. Zhou et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2016)
Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model
Shinji Yamazaki et al.
DRUG METABOLISM AND DISPOSITION (2015)
Evaluation of Various Static and Dynamic Modeling Methods to Predict Clinical CYP3A Induction Using In Vitro CYP3A4 mRNA Induction Data
H. J. Einolfl et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Impact of nonlinear midazolam pharmacokinetics on the magnitude of the midazolam-ketoconazole interaction in rats
Ragini Vuppugalla et al.
XENOBIOTICA (2012)
Clinical Pharmacokinetics of Systemically Administered Antimycotics
Romuald Bellmann
CURRENT CLINICAL PHARMACOLOGY (2007)
Canine intestinal contents vs. simulated media for the assessment of solubility of two weak bases in the human small intestinal contents
Lida Kalantzi et al.
PHARMACEUTICAL RESEARCH (2006)
Prediction of in vivo drug-drug interactions from in vitro data - Factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4
Hayley S. Brown et al.
CLINICAL PHARMACOKINETICS (2006)
pH-dependent dissolution in vitro and absorption in vivo of weakly basic drugs:: Development of a canine model
R Zhou et al.
PHARMACEUTICAL RESEARCH (2005)
Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition
GK Dresser et al.
CLINICAL PHARMACOKINETICS (2000)
Share Paper
